Understanding the Unique Role of HER3 in Oncogenesis
February 4, 2022
February 4, 2023
Scroll to the Bottom of this Information to Begin this Course
This activity is jointly provided by Postgraduate Institute for Medicine and Excalibur Medical Education.
This activity is supported by an independent educational grant from Daiichi Sankyo, Inc.
- Physicians — maximum of 0.50 AMA PRA Category 1 Credit(s)™
All other healthcare professionals completing this course will be issued a statement of participation.
This activity is designed to meet the educational needs of academic and community oncologists, along with other providers who assist in the management of non-small cell lung cancer (NSCLC), metastatic breast cancer (MBC), and colorectal cancer patients.
This activity will explore the clinical evidence surrounding the role of HER3 in various tumor types.
Upon completion of this activity, participants should be better able to:
- Recognize the role of the HER family, and particularly HER3, in oncogenesis
- Identify the common causes of disease progression in patients with advanced NSCLC, metastatic breast, colorectal, and other cancers, focusing specifically on treatment failure to epidermal growth factor receptor or anti-estrogen-based therapies
- Explain the mechanism of disease of HER3 and HER3-directed antibody drug conjugates (ADCs) under investigation for the treatment of EGFR TKI-resistant NSCLC, breast, and colorectal cancer
Helena A. Yu, MD
Memorial Sloan Kettering Cancer Center
New York, NY
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Excalibur Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
- Helena A. Yu, MD
- Consulting fees: AstraZeneca, Black Diamond, Blueprint, Cullinan, Daiichi, Janssen
- Contracted Research: Research funding to my institution from AstraZeneca, Cullinan, Daiichi, Janssen, Lilly, Novartis, Pfizer
The PIM planners and others have nothing to disclose. The Excalibur Medical Education planners and others have nothing to disclose.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
For CME questions please contact: email@example.com